Table 2.
Plasma cytokine portraits of primary and SLE-related AIHA patients (pg/ml)
| Primary (n = 19) | SLE-related (n = 18) | Health control (n = 10) | |
|---|---|---|---|
| IFN-γ | 30.93 (19.53-45.66) | 36.83 (26.72-69.23) | 48.78 (38.10-61.94) |
| I-309/CCL1 | 65.26 (38.62-108.86)※ | 123.78 (81.56-192.06) | 179.66 (96.27-194.22) |
| MCP-1/CCL2 | 557.52 (366.62-709.14)※ | 683.57 (546.29-1070.0)※ | 284.96 (200.73-372.66) |
| MIP-1α/CCL3 | 77.23 (64.74-119.83) | 114.56 (78.54-162.82) | 115.37 (93.05-133.28) |
| MIP-1β/CCL4 | 23.73 (12.38-38.30)※ | 18.75 (11.11-33.73)※ | 5.05 (4.02-10.22) |
| MIP-1δ/CCL15 (×104) | 0.88 (0.72-1.16) | 0.55 (0.29-1.05) | 1.37 (0.56-1.85) |
| RANTES/CCL5 (×103) | 4.12 (2.40-7.38) | 5.89 (1.52-16.33) | 5.03 (1.94-7.24) |
| Eotaxin/CCL11 | 95.41 (64.34-138.11) | 118.44 (91.65-166.06) | 120.81 (92.81-133.95) |
| Eotaxin-2/CCL24 | 623.34 (329.62-810.59)※ | 412.51 (282.29-720.39) | 289.56 (206.08-370.20) |
| MIG/CXCL9 (×103) | 2.89 (1.95-5.15) | 3.11 (2.02-10.26) | 2.36 (1.82-4.12) |
| BLC/CXCL13 | 147.90 (104.11-436.02)※ | 203.45 (110.74-290.42)※ | 69.14 (56.24-100.39) |
| ICAM-1 (×105) | 1.34 (0.66-1.99) | 0.60 (0.49-0.93)※ | 1.88 (0.95-2.73) |
| G-CSF | 11.29 (4.15-24.12) | 16.44 (12.83-22.74) | 25.12 (14.47-28.15) |
| M-CSF | 35.48 (19.14-66.10)※ | 82.47 (29.22-181.19) # | 122.47 (71.49-150.85) |
| GM-CSF | 36.70 (23.65-48.62) | 41.60 (25.59-78.01) | 48.22 (39.60-72.10) |
| IL-1α | 7.51 (3.00-26.10)※ | 27.28 (7.85-60.07)# | 42.77 (24.27-53.30) |
| IL-1β | 63.98 (40.83-159.84) | 133.24 (89.85-223.31)# | 203.08 (98.42-223.41) |
| IL-1ra | 202.27 (121.20-368.22) | 416.94 (192.30-563.72) | 121.82 (89.31-196.76) |
| IL-2 | 9.04 (5.14-12.20) | 9.81 (6.83-18.59) | 11.12 (9.43-13.68) |
| IL-4 | 8.98 (6.04-16.53) | 25.87 (8.61-67.04)# | 29.64 (13.45-35.24) |
| IL-5 | 67.17 (46.65-116.94)※ | 104.56 (55.58-155.07) | 150.04 (103.54-176.69) |
| IL-6 | 52.20 (40.23-76.39) | 71.41 (40.80-106.07) | 62.45 (52.92-72.92) |
| IL-6sR (×103) | 4.05 (3.49-4.70) | 4.31 (3.45-5.17) | 4.57 (3.78-4.86) |
| IL-7 | 72.16 (44.68-115.49) | 85.55 (59.18-147.61) | 81.55 (72.15-110.65) |
| IL-8/CXCL8 | 8.66 (5.81-26.17)※ | 19.15 (9.23-26.68)※ | 4.84 (3.95-7.21) |
| IL-10 | 26.68 (17.98-42.12) | 37.50 (19.68-71.93) | 15.22 (14.40-26.26) |
| IL-11 | 205.97 (61.19-342.55)※ | 324.66 (174.49-546.81)※ | 666.37 (487.65-861.28) |
| IL-12p40 | 301.15 (83.39-558.00) | 570.79 (234.36-1207.2) | 277.58 (151.29-403.68) |
| IL-12p70 | 4.96 (2.52-9.90)※ | 16.41 (4.91-27.76)# | 17.04 (10.93-22.00) |
| IL-13 | 6.82 (4.40-9.99)※ | 10.18 (5.87-14.10) | 10.87 (10.53-14.63) |
| IL-15 | 149.92 (61.75-478.57) | 130.10 (87.61-216.20) | 194.64 (169.31-233.75) |
| IL-16 | 127.04 (87.19-188.99) | 187.65 (105.95-365.92) | 168.00 (102.51-214.64) |
| IL-17 | 89.62 (36.65-197.82)※ | 184.42 (78.67-298.60)※ | 438.99 (279.09-667.12) |
| TIMP-1 (×104) | 1.15 (0.87-1.46) | 1.63 (0.77-3.29) | 2.18 (1.13-3.67) |
| TIMP-2 (×104) | 1.62 (1.37-1.78) | 1.97 (1.40-2.56) | 1.97 (1.66-2.26) |
| PDGF-BB (×103) | 2.45 (1.79-2.83) | 2.39 (1.99-3.00) | 1.56 (1.44-2.00) |
| TNFα | 57.42 (31.45-106.25) | 85.66 (36.50-121.91) | 104.09 (87.59-148.24) |
| TNFβ | 28.24 (26.75-71.80)※ | 46.24 (27.84-128.56) | 92.78 (64.99-144.54) |
| sTNFRI (×103) | 3.41 (2.63-3.68)※ | 4.43 (2.67-5.18)※ | 1.21 (0.89-1.72) |
| sTNFRII (×103) | 3.30 (2.12-4.99)※ | 6.99 (3.84-11.24)※# | 2.05 (1.37-2.70) |
Data are presented as median (interquartile range). The level of significance for pairwise comparisons was adjusted when multiple comparisons were performed (p = 0.05 / 3 = 0.017).
※p <0.017 compared to health control; #p <0.017 compared to primary AIHA.